Skip to main content
. 2022 Feb 14;14(4):940. doi: 10.3390/cancers14040940

Table 3.

Different strategies targeting TGF-β signaling components for cancer therapy.

Mode of Action Target Name Type References
TGF-β ligand inhibitors TGF-β1, TGF-β2, and TGF-β3 Fresolimumab Neutralizing antibody [318]
TGF-β1, TGF-β2, and TGF-β3 SAR439459 Neutralizing antibody [320]
TGF-β1, TGF-β2, and TGF-β3 NIS793 Neutralizing antibody [320]
TGF-β1 and TGF-β3 AVID200 Ligand trap [308]
TGF-β1 Metelimumab Neutralizing antibody [324]
TGF-β2 Trabedersen Antisense oligonucleotide [308]
TGF-β2 Lucanix Vaccine [321]
TGF-β1 LY2382770 Neutralizing antibody [325]
TGF-β1 SRK-181 Neutralizing antibody [321]
TGF-β2 Lerdelimumab Monoclonal antibody [326]
TGF-β1 Disitertide Peptide [326]
TGF-β1 and TGF-β2 FANG Vaccine Vaccine [326]
TGF-β1 ISTH0036 Antisense oligonucleotide [325]
TGF-β receptor inhibitors TGFβRI Galunisertib Small molecule inhibitor [318]
TGFβRI and TGFβRII LY2109761 Small molecule inhibitor [327]
TGFβRI PF-03446962 Monoclonal antibody [318]
TGFβRI IMC-TR1 Monoclonal antibody [320]
TGFβRI Vactosertib Small molecule inhibitor [318]
TGFβRI and TGFβRII P144 Ligand trap [325]